CAR-302,196: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
== Chimeric Antigen Receptor (CAR) T-cell Therapy == | |||
[[File:CAR-302,196_structure.png|thumb|right|Structure of CAR-302,196]] | |||
CAR-302, | |||
Chimeric Antigen Receptor (CAR) T-cell therapy is a form of [[immunotherapy]] that uses specially altered [[T cells]] to fight [[cancer]]. This therapy involves modifying a patient's T cells to express a CAR, which is a synthetic receptor that can recognize and bind to specific proteins on the surface of cancer cells. | |||
== | == Mechanism of Action == | ||
CAR T-cell therapy works by harnessing the body's own immune system to target and destroy cancer cells. The process begins with the collection of T cells from the patient. These cells are then genetically engineered in the laboratory to express a CAR that targets a specific [[antigen]] found on the cancer cells. | |||
[[ | Once the CAR T cells are infused back into the patient, they seek out and bind to the cancer cells. The binding of the CAR to the antigen activates the T cells, triggering them to proliferate and kill the cancer cells. This targeted approach allows for the selective destruction of cancer cells while sparing normal cells. | ||
[[ | |||
[[ | == Development of CAR T-cell Therapy == | ||
The development of CAR T-cell therapy has been a significant advancement in the field of [[oncology]]. The first generation of CARs consisted of a single-chain variable fragment (scFv) derived from an [[antibody]], linked to a T-cell activation domain. Subsequent generations have incorporated additional co-stimulatory domains to enhance the efficacy and persistence of the CAR T cells. | |||
[[File:CAR-302,196.png|thumb|left|CAR-302,196 in action]] | |||
== Applications == | |||
CAR T-cell therapy has shown remarkable success in treating certain types of [[hematologic malignancies]], such as [[acute lymphoblastic leukemia]] (ALL) and [[non-Hodgkin lymphoma]]. Research is ongoing to expand its use to other types of cancer, including solid tumors. | |||
== Challenges and Considerations == | |||
Despite its promise, CAR T-cell therapy presents several challenges. One major concern is the potential for severe side effects, such as [[cytokine release syndrome]] (CRS) and [[neurotoxicity]]. Additionally, the therapy is complex and costly, requiring specialized facilities and expertise. | |||
== Future Directions == | |||
Ongoing research aims to improve the safety and efficacy of CAR T-cell therapy. Strategies include the development of "off-the-shelf" CAR T cells, which could be used in multiple patients, and the engineering of CARs to target multiple antigens to prevent cancer relapse. | |||
== Related Pages == | |||
* [[Immunotherapy]] | |||
* [[T cells]] | |||
* [[Cancer]] | |||
* [[Antigen]] | |||
* [[Acute lymphoblastic leukemia]] | |||
[[Category:Immunotherapy]] | |||
[[Category:Cancer treatments]] | |||
Revision as of 12:06, 15 February 2025
Chimeric Antigen Receptor (CAR) T-cell Therapy
Chimeric Antigen Receptor (CAR) T-cell therapy is a form of immunotherapy that uses specially altered T cells to fight cancer. This therapy involves modifying a patient's T cells to express a CAR, which is a synthetic receptor that can recognize and bind to specific proteins on the surface of cancer cells.
Mechanism of Action
CAR T-cell therapy works by harnessing the body's own immune system to target and destroy cancer cells. The process begins with the collection of T cells from the patient. These cells are then genetically engineered in the laboratory to express a CAR that targets a specific antigen found on the cancer cells.
Once the CAR T cells are infused back into the patient, they seek out and bind to the cancer cells. The binding of the CAR to the antigen activates the T cells, triggering them to proliferate and kill the cancer cells. This targeted approach allows for the selective destruction of cancer cells while sparing normal cells.
Development of CAR T-cell Therapy
The development of CAR T-cell therapy has been a significant advancement in the field of oncology. The first generation of CARs consisted of a single-chain variable fragment (scFv) derived from an antibody, linked to a T-cell activation domain. Subsequent generations have incorporated additional co-stimulatory domains to enhance the efficacy and persistence of the CAR T cells.
Applications
CAR T-cell therapy has shown remarkable success in treating certain types of hematologic malignancies, such as acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma. Research is ongoing to expand its use to other types of cancer, including solid tumors.
Challenges and Considerations
Despite its promise, CAR T-cell therapy presents several challenges. One major concern is the potential for severe side effects, such as cytokine release syndrome (CRS) and neurotoxicity. Additionally, the therapy is complex and costly, requiring specialized facilities and expertise.
Future Directions
Ongoing research aims to improve the safety and efficacy of CAR T-cell therapy. Strategies include the development of "off-the-shelf" CAR T cells, which could be used in multiple patients, and the engineering of CARs to target multiple antigens to prevent cancer relapse.
